Moderna Announces Superiority of Bivalent Booster
https://www.biospace.com/article/moderna-s-new-bivalent-booster-proves-more-effective-vs-covid-19/
In the latest clinical study involving 300 participants, Moderna researchers found that the booster delivered a 2.20-fold and 2.15-fold rise in neutralizing antibody titer volumes versus the Omicron variant in participants after one and six months. Some patients were given 50 µg, while others received 100 µg. In terms of adverse events, those who got 50 µg of mRNA-1273.211 experienced the same reactions as those who got the earlier mRNA-1273 booster.
